Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.

"I believe Journavx could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

I share management's optimism in this ... They must improve on Journavx if they are to truly dominate the non-opioid pain market as they hope to. Based on all these unknowns, it feels speculative ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Through this acquisition, LLY intends to strengthen its neuroscience pipeline and advance non-opioid medicines for pain management ... Vertex Pharmaceuticals’ Journavx — also a Nav1.8 ...

Vertex's Journavx offers patients and doctors an ... And the company's entrance into the pain management market may be a game-changing moment, opening the door to a huge new revenue stream.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.